Chemomab Therapeutics Ltd ADR CMMB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CMMB is a good fit for your portfolio.
News
-
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
-
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
-
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
-
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
-
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
-
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
-
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
-
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
Trading Information
- Previous Close Price
- $0.66
- Day Range
- $0.62–0.65
- 52-Week Range
- $0.42–1.89
- Bid/Ask
- $0.62 / $0.66
- Market Cap
- $9.09 Mil
- Volume/Avg
- 23,560 / 230,484
Key Statistics
- Price/Earnings (Normalized)
- 0.34
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 20
- Website
- https://www.chemomab.com
Valuation
|
Metric
|
CMMB
|
|---|---|
Price/Earnings (Normalized) | 0.34 |
Price/Book Value | 0.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CMMB
Financial Strength
|
Metric
|
CMMB
|
|---|---|
Quick Ratio | 4.15 |
Current Ratio | 4.32 |
Interest Coverage | — |
Quick Ratio
CMMB
Profitability
|
Metric
|
CMMB
|
|---|---|
Return on Assets (Normalized) | −70.44% |
Return on Equity (Normalized) | −88.13% |
Return on Invested Capital (Normalized) | −92.11% |
Return on Assets
CMMB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hbnrfwdvh | Tzg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qjgcycrt | Bqbmcrp | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vmqysdv | Xdgvb | $97.8 Bil | |
MRNA
| Moderna Inc | Jxwcttz | Qvnb | $41.3 Bil | |
ARGX
| argenx SE ADR | Zcxrzyrmh | Hcq | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jzlgldvj | Qzxkw | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fycszvy | Rpqlkx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zkpnfdnq | Rvbchs | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vsbvtmqlv | Knrwnc | $12.5 Bil | |
INCY
| Incyte Corp | Wfsfbgns | Vbrppx | $11.6 Bil |